Navamedic ASA
OB:NAVA Rapport sur les actions
Capitalisation boursière : NOK 431.0m
Ajouter à la liste de surveillanceNavamedic Bilan de santé
Santé financière contrôle des critères 4/6 Navamedic possède un total de capitaux propres de NOK264.1M et une dette totale de NOK121.5M, ce qui porte son ratio d'endettement à 46%. Son actif total et son passif total sont NOK527.5M et de NOK263.4M. L'EBIT de Navamedic est NOK42.1M ce qui fait que son ratio de couverture des intérêts 13.4. Elle dispose de liquidités et de placements à court terme de NOK46.5M.
Informations clés Ratio de couverture des intérêts 13.4x Argent liquide NOK 46.47m Fonds propres NOK 264.13m Total du passif NOK 263.37m Total des actifs NOK 527.50m
Mises à jour récentes de la santé financière
Afficher toutes les mises à jour
Consensus EPS estimates fall by 21% Nov 12
Chief Financial Officer recently bought kr476k worth of stock Nov 08
Navamedic Launches Eroxon in Finland Nov 07
New minor risk - Profit margin trend Nov 06
Third quarter 2024 earnings released Nov 01
Investor sentiment deteriorates as stock falls 17% Nov 01
Chief Executive Officer exercised options to buy kr2.2m worth of stock. Sep 11
Consensus EPS estimates fall by 12% Aug 25
Director recently bought kr1.5m worth of stock Aug 22
Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023) Aug 18
Price target decreased by 7.1% to kr45.50 Aug 14
First quarter 2024 earnings released May 02 An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. Mar 13
Consensus EPS estimates increase by 24% Mar 07
Consensus EPS estimates fall by 28%, revenue upgraded Feb 27
New minor risk - Earnings quality Feb 18
Full year 2023 earnings released Feb 16 Navamedic ASA to Report First Half, 2024 Results on Aug 16, 2024
Third quarter 2023 earnings released Nov 06
Consensus EPS estimates increase by 10% Oct 29
Is Navamedic (OB:NAVA) Using Too Much Debt? Sep 19
Investor sentiment improves as stock rises 15% Sep 12
Consensus EPS estimates fall by 53% Aug 22
New minor risk - Financial position Aug 15
Second quarter 2023 earnings: Revenues exceed analyst expectations Aug 15
Consensus EPS estimates fall by 15% Aug 06
Consensus EPS estimates fall by 16%, revenue upgraded Jul 26
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors Jun 02
First quarter 2023 earnings released May 12
Price target increased by 8.7% to kr50.00 Feb 27
Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly Feb 18
Full year 2022 earnings released Feb 17
Consensus EPS estimates increase by 20%, revenue downgraded Feb 10
Navamedic ASA Launches Modifast in Norway Jan 31 Navamedic ASA to Report Q3, 2023 Results on Nov 01, 2023
Price target increased to kr48.00 Nov 16
No independent directors Nov 16
Consensus EPS estimates increase by 19% Nov 10
Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality Nov 09
Third quarter 2022 earnings released Nov 02
Is Navamedic (OB:NAVA) A Risky Investment? Nov 02
Consensus forecasts updated Oct 25
Price target decreased to kr44.00 Oct 24
Navamedic ASA Launches Forlaxgo® Oct 20
Consensus EPS estimates increase by 50% Aug 23
Consensus EPS estimates increase by 30% Aug 11
Chief Financial Officer exercised options to buy kr2.1m worth of stock. Jun 02
Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million . Jun 02
Consensus forecasts updated May 17
First quarter 2022 earnings: Revenues exceed analyst expectations May 10
Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB. May 06
Price target increased to kr50.00 Apr 27
No independent directors Apr 27
Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden Feb 22
Full year 2021 earnings: Revenues exceed analyst expectations Feb 18
Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea Feb 17
Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022 Dec 24
Third quarter 2021 earnings released Nov 05
We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt Sep 04
Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020) Aug 18
Navamedic ASA Announces the Launch of New Products in the Nordics Jun 02
Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden May 21
First quarter 2021 earnings released May 12
Is Navamedic (OB:NAVA) Using Too Much Debt? Apr 12
New 90-day high: kr29.00 Mar 02
Full year 2020 earnings released Feb 20
If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today Feb 18
New 90-day high: kr22.60 Feb 09
Is Navamedic (OB:NAVA) Using Debt Sensibly? Dec 07 Navamedic ASA to Report Q2, 2021 Results on Aug 13, 2021
New 90-day low: kr17.45 Nov 04
New 90-day low: kr18.20 Oct 15
Chief Executive Officer exercised options to buy kr2.3m worth of stock. Oct 08
New 90-day low: kr18.50 Sep 22
Earnings released Aug 21
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de NAVA ( NOK263.9M ) dépassent ses passifs à court terme ( NOK161.1M ).
Passif à long terme: Les actifs à court terme de NAVA ( NOK263.9M ) dépassent ses passifs à long terme ( NOK102.3M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de NAVA ( 28.4% ) est considéré comme satisfaisant .
Réduire la dette: Le ratio d'endettement de NAVA est passé de 33.3% à 46% au cours des 5 dernières années.
Couverture de la dette: La dette de NAVA n'est pas bien couverte par le flux de trésorerie opérationnel ( 7.6% ).
Couverture des intérêts: Les paiements d'intérêts de NAVA sur sa dette sont bien couverts par l' EBIT ( 13.4 x couverture).
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}